307 related articles for article (PubMed ID: 21200420)
41. The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Tayyebi M; Darchini-Maragheh E; Layegh P; Kiafar B; Goyonlo VM
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009241. PubMed ID: 33739976
[TBL] [Abstract][Full Text] [Related]
42. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
Rugani JN; Quaresma PF; Gontijo CF; Soares RP; Monte-Neto RL
Biomed Pharmacother; 2018 Dec; 108():1170-1180. PubMed ID: 30372818
[TBL] [Abstract][Full Text] [Related]
43. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
44. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
[TBL] [Abstract][Full Text] [Related]
46. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
47. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
[TBL] [Abstract][Full Text] [Related]
48. A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.
Martins SS; Barroso DH; Rodrigues BC; da Motta JOC; Freire GSM; Pereira LIA; Kurisky PS; Gomes CM; Sampaio RNR
Front Cell Infect Microbiol; 2021; 11():700323. PubMed ID: 34277476
[TBL] [Abstract][Full Text] [Related]
49. Miltefosine: oral treatment of leishmaniasis.
Soto J; Soto P
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
[TBL] [Abstract][Full Text] [Related]
50. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
Machado PRL; Lago A; Cardoso TM; Magalhaes A; Carvalho LP; Lago T; Carvalho AM; Costa R; Carvalho EM
Emerg Infect Dis; 2024 Mar; 30(3):510-518. PubMed ID: 38407142
[TBL] [Abstract][Full Text] [Related]
51. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
52. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
Tappe D; Müller A; Stich A
Am J Trop Med Hyg; 2010 Jan; 82(1):1-3. PubMed ID: 20064985
[No Abstract] [Full Text] [Related]
53. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Castro MDM; Cossio A; Velasco C; Osorio L
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Santarem AA; Greggianin GF; Debastiani RG; Ribeiro JB; Polli DA; Sampaio RN
Rev Soc Bras Med Trop; 2014 Jul; 47(4):517-20. PubMed ID: 25229296
[TBL] [Abstract][Full Text] [Related]
55. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.
Gadelha EPN; Ramasawmy R; da Costa Oliveira B; Morais Rocha N; de Oliveira Guerra JA; Allan Villa Rouco da Silva G; Gabrielle Ramos de Mesquita T; Chrusciak Talhari Cortez C; Chrusciak Talhari A
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006850. PubMed ID: 30379814
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
Crone CG; Helleberg M
J Travel Med; 2020 Feb; 27(1):. PubMed ID: 31776570
[No Abstract] [Full Text] [Related]
57. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
Eichner S; Thoma-Uszynski S; Herrgott I; Sebald H; Debus A; Tsianakas A; Ehrchen J; Harms G; Simon M; Sunderkötter C; Bogdan C
Eur J Dermatol; 2013 Apr; 23(2):218-23. PubMed ID: 23557633
[TBL] [Abstract][Full Text] [Related]
58. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
59. A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.
Ramanathan R; Talaat KR; Fedorko DP; Mahanty S; Nash TE
Am J Trop Med Hyg; 2011 Jan; 84(1):109-17. PubMed ID: 21212212
[TBL] [Abstract][Full Text] [Related]
60. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
